重视干眼药物的研发与研究

Attach great importance to the drug research and development in dry eye

干眼是一种常见的慢性多因素眼表疾病,严重影响患者的生活质量甚至视力。由于其患病率高、发病机制复杂、治疗周期长且效果欠佳,干眼已成为重要的社会公共问题。干眼药物治疗包括泪液替代治疗、抗炎治疗及针对性的抗菌治疗,然而尚不能完全解决临床需求。近年来,随着对干眼发病机制认识的不断深入,国内外的干眼药物研究进展快速,多种新型抗炎制剂、抗氧化剂和促泪膜稳定性的药物已进入临床。值得说明的是,干眼的药物研发仍然有很大空间,尤其是针对中重度干眼的治疗药物。眼科医师和研究者应充分认识并关注干眼新药的研发和研究进展,以更好地服务广大患者。

Dry eye is a common chronic and multifactorial ocular surface disease,seriously affects patients’quality of life and even vision.Owning to its high prevalence,complicated pathophysiology,prolonged treatment cycle,dry eye has become an important social public problem.Currently,drug therapy for dry eye mainly includes tear substitutes therapy,anti-inflammatory therapy and targeted antibacterial therapy.However,there remains unmet needs in clinical treatment.In recent years,with the insightful research on the pathogenesis of dry eye,advanced progress has been achieved in the research of dry eye agents at home and abroad,with a variety of new anti-inflammatory agent,antioxidants agent and tear film stability drugs coming into view.It should be noted that there is still a lot to explore in the research and development of dry eye drugs,especially for mild and moderate dry eye treatment.Ophthalmologists and researchers should be fully aware of and keep updated on the research progress of new medications for dry eye,in order to better serve the patients.